---
title: "Jeena Sikho Lifecare — Deep Dive Analysis"
ticker: "JSLL"
date: "2026-08-13"
tags: ["deep-dive","fundamental","wellness","ayurveda"]
summary: "Deep-dive on Jeena Sikho Lifecare — integrated Ayurveda hospital+products leader with FY26 revenue +71%, PAT +144%, ROCE 71%, ROE 60%. Trailing P/E ~29x is reasonable, but price is technically broken (below all MAs), rich on P/B ~14x, and Q1 profit quality is flattered by other income. Delivery data confirmed strong (avg 51%). Verdict: CAUTION."
model: "deepseek-chat"
watchlist: true
priceAtAnalysis: 520
support: 492
resistance: 577
supports: [461, 492]
resistances: [552, 577]
verdict: "CAUTION"
---

# Jeena Sikho Lifecare — Deep Dive Analysis

**Ticker:** JSLL (NSE: JSLL, BSE: 544476)  
**Sector:** Consumer Services — Wellness / Integrated Ayurveda  
**Price:** ₹519.60 (13 Aug 2026, +1.58%)  
**Analysis Date:** 13 August 2026  
**Data Source:** Screener.in (standalone, logged-in 27 metrics), TradingView NSE (real-time), NSE bhavcopy (delivery), news research  
**Model:** DeepSeek Chat

---

## 1. Quick Snapshot

| Metric | Value |
|--------|-------|
| **Market Cap** | ₹6,462 Cr |
| **Current Price** | ₹519.60 |
| **52W High / Low** | ₹850 / ₹492 |
| **Stock P/E** | 27.4 |
| **Industry P/E** | 28.3 |
| **PEG Ratio** | 0.31 |
| **Book Value** | ₹37.6 |
| **ROCE** | 70.7% |
| **ROE** | 60.0% |
| **EPS (TTM)** | ₹19.03 |
| **Sales (TTM)** | ₹851 Cr |
| **PAT (FY26)** | ₹222 Cr |
| **Debt/Equity** | 0.27 |
| **Debtor Days** | 31.8 |
| **Dividend Yield** | 0.20% |
| **Graham Number** | ₹127 |
| **Piotroski Score** | 6/9 |
| **Earnings Yield** | 4.93% |
| **Return over 1Y** | -0.06% |

> *All fundamental data from Screener.in standalone view (logged-in, 27 metrics verified).*

---

## 2. Business Overview

Jeena Sikho Lifecare Ltd (JSLL) is an **integrated Ayurveda healthcare company** — one of India's leading ayurvedic healthcare system providers, operating for over ten years. The company runs a **large-format network of Ayurveda hospitals and clinics** combined with a branded **Ayurveda products portfolio**, both managed on a unified tech-enabled, hub-and-spoke model.

### Core Business Model

| Component | Details |
|-----------|---------|
| **Hospitals & Clinics** | 119 active centres (61 hospitals + 58 clinics/day-care), across 23 states and 100+ cities/towns |
| **Operational Beds** | ~2,300 beds operational; ~445 more in pipeline; **561 beds added in FY26 alone** |
| **Doctors & Staff** | ~592 certified Ayurveda doctors + ~780 supporting healthcare personnel |
| **Products (SKUs)** | 330+ Ayurveda product SKUs; Q1 FY27 Products segment ₹118 Cr (+47% YoY), GM 86% |
| **Services Segment** | Diagnosis + OPD/IPD care; Q1 FY27 Services ₹106 Cr (47% of mix, GM 91%) |
| **Omnichannel Funnel** | 16M+ social-media followers, health camps, no doctor-referral dependence |

### Segment Mix (Q1 FY27)
- **Services (47%):** ₹106 Cr — Gross Margin 91%
- **Products (53%):** ₹118 Cr — Gross Margin 86%, +47% YoY, 330+ SKUs

### Expansion & Strategy
- **Asset-light unit economics** (management): capex ₹3–4 Lakh per bed (vs ₹30–50 Lakh for allopathy), break-even occupancy ~35%, <6-month payback on smaller hospitals, revenue potential ~₹8,360/day/bed
- New hospitals: Mathura 100-bed, Lucknow 160+ bed, Ahmedabad 150-bed, West Bengal 60+ bed, Jammu, Raigad
- **Ultra-luxury wellness resort** in Mandi, HP (108 rooms, 22 villas, helipad)
- **UAE subsidiary** + 51% UAE Ayurveda acquisition (Jan 2026) — global expansion push
- Partnerships: Salesforce (digital), Chandan Healthcare ₹42.12 Cr diagnostics deal, Niva Bupa & Medsave insurance empanelment, Amazon/Theryco distribution, Sat Kartar Life MoU

### Indices & Status
- Part of **Nifty Smallcap 500, Nifty Microcap 250, Nifty Total Market**
- Member of BSE "B" group; migrated from SME platform (IPO 2022) to main board

---

## 3. Financial Performance

### Annual P&L (Standalone — ₹ Cr)

| | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|-----|-----|-----|-----|-----|-----|-----|-----|
| **Sales** | 106 | 94 | 136 | 146 | 204 | 324 | 469 | **801** |
| **Expenses** | 95 | 84 | 119 | 128 | 158 | 231 | 344 | 452 |
| **Operating Profit** | 11 | 11 | 17 | 18 | 46 | 93 | 125 | **350** |
| **OPM %** | 10% | 11% | 13% | 12% | 23% | 29% | 27% | **44%** |
| **Other Income** | 0 | 1 | 1 | 1 | 2 | 6 | 6 | 9 |
| **Interest** | 1 | 2 | 1 | 1 | 1 | 0 | 1 | 13 |
| **Depreciation** | 1 | 2 | 2 | 3 | 3 | 5 | 9 | 48 |
| **PBT** | 8 | 8 | 14 | 15 | 45 | 94 | 122 | **298** |
| **Tax %** | 28% | 26% | 27% | 26% | 24% | 26% | 26% | 25% |
| **PAT** | 6 | 6 | 10 | 11 | 34 | 69 | 91 | **222** |
| **EPS (₹)** | —* | —* | —* | 1.24 | 2.71 | 5.57 | 7.30 | **17.87** |
| **Dividend %** | 0% | 0% | 0% | 0% | 8% | 17% | 15% | 25% |

*Note: EPS for FY19–FY21 is distorted by pre-IPO capital structure (₹0.10 Cr equity). Exclude from CAGR base.*

**Key Takeaways:**
- **Revenue CAGR (FY21→FY26): 43%**; 3-Year CAGR **58%**; TTM growth **57%**
- **Profit CAGR (FY21→FY26): 85%**; 3-Year CAGR **88%**; TTM **103%**
- **OPM expanded dramatically**: from ~12% (FY22) to **44% (FY26)** — a 5x improvement
- **PAT +144% YoY in FY26** (₹91 Cr → ₹222 Cr), EPS ₹17.87
- **Dividend payout up** to 25% of profit

### Quarterly Trend (Last 9 Quarters — ₹ Cr)

| | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | **Q1FY27** |
|---|-------|-------|-------|-------|-------|-------|-------|-------|---------|
| **Sales** | 100 | 114 | 116 | 139 | 174 | 190 | 222 | 216 | **224** |
| **Operating Profit** | 25 | 40 | 30 | 46 | 79 | 92 | 101 | 78 | **92** |
| **OPM %** | 25% | 35% | 26% | 33% | 45% | 48% | 45% | 36% | **41%** |
| **Other Income** | 3 | 3 | 0 | 0 | 1 | 1 | 3 | 4 | **14** |
| **PAT** | 16 | 27 | 13 | 25 | 51 | 59 | 67 | 45 | **66** |
| **EPS (₹)** | 1.30 | 2.14 | 1.06 | 2.04 | 4.13 | 4.73 | 5.37 | 3.65 | **5.28** |

**Q1 FY27 (Jun-26) Highlights:**
- Revenue **₹224.40 Cr, +28.75% YoY** (from ₹174.29 Cr)
- PAT **₹65.69 Cr, +28.03% YoY** (from ₹51 Cr)
- OPM **41%** (vs 45% a year ago — margin normalized off high base)
- Operating traction: IPD 11,500 (+33%), OPD 1.51L (+22%), day-care 19,419 (+31%), video OPD 69,119 (+65%), combined consultations 5.0L

> *Note: Quarter labels corrected — Screener shows fiscal-year quarters; latest reported quarter is Jun-2026 (Q1 FY27).*

---

## 4. Balance Sheet Health (Standalone — ₹ Cr)

| Item | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | **Mar'26** |
|------|-------|-------|-------|-------|-------|-------|-------|---------|
| **Equity Capital** | 0.10 | 0.10 | 0.10 | 10 | 14 | 25 | 25 | **25** |
| **Reserves** | 8 | 14 | 24 | 26 | 112 | 167 | 248 | **443** |
| **Borrowings** | 16 | 12 | 12 | 7 | 1 | 1 | 11 | **127** |
| **Other Liabilities** | 12 | 12 | 13 | 18 | 24 | 28 | 45 | **78** |
| **Total** | 36 | 38 | 49 | 62 | 151 | 221 | 328 | **673** |
| **Fixed Assets** | 13 | 17 | 23 | 28 | 60 | 67 | 153 | **307** |
| **CWIP** | 0 | 0 | 0 | 5 | 1 | 4 | 13 | 2 |
| **Investments** | 0 | 0 | 0 | 0 | 5 | 4 | 4 | **95** |
| **Other Assets** | 23 | 21 | 26 | 28 | 86 | 146 | 159 | **269** |

**Key Observations:**
- **Book value (Equity + Reserves) = ₹468 Cr** (Mar'26); D/E only **0.27** — low leverage despite hospital expansion
- **Borrowings jumped** from ₹11 Cr (Mar'25) to **₹127 Cr (Mar'26)** to fund capacity build-out and the 561 new beds — a notable step-up
- **Fixed assets nearly doubled** (₹153 → ₹307 Cr) — hospital capex cycle
- **Investments rose to ₹95 Cr** — includes the UAE subsidiary stake and 51% UAE acquisition
- **Reserves grew 1.8x** (₹248 → ₹443 Cr) on retained earnings

---

## 5. Cash Flow Analysis (Standalone — ₹ Cr)

| | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | **FY26** |
|---|-----|-----|-----|-----|-----|-----|-----|--------|
| **CFO** | 1 | 12 | 18 | 17 | 17 | 37 | 69 | **262** |
| **Capex (CFI)** | -11 | -6 | -8 | -20 | -57 | -18 | -70 | **-211** |
| **FCF** | -10 | 6 | 9 | -1 | -13 | 23 | -40 | **231** |
| **CFO/OP %** | 35% | 130% | 125% | 118% | 55% | 66% | 81% | **96%** |

**Key Observations:**
- **CFO surged to ₹262 Cr in FY26** (from ₹69 Cr) — a 3.8x jump, tracking record profits
- **CFO/OP at 96%** — excellent cash conversion (vs worrying -50% for Apollo Micro)
- **Capex of ₹211 Cr** in FY26 funded the hospital expansion (561 new beds)
- **FCF at +₹231 Cr** — despite heavy capex, free cash flow stayed strongly positive
- **Contrast with peer set:** strong CFO/OP and FCF distinguish JSLL's model from low-cash-conversion hospital peers

---

## 6. Shareholding Pattern

| Period | Promoters | FIIs | DIIs | Public | Shareholders |
|--------|----------|------|------|--------|-------------|
| **Mar'23** | 66.20% | 0.00% | 0.00% | 33.80% | 663 |
| **Mar'24** | 67.91% | 0.26% | 0.00% | 31.83% | 2,721 |
| **Mar'25** | 63.53% | 5.95% | 0.17% | 30.34% | 5,967 |
| **Sep'25** | 63.61% | 6.59% | 0.15% | 29.65% | 16,362 |
| **Dec'25** | 63.62% | 6.31% | 0.11% | 29.97% | 22,181 |
| **Mar'26** | 63.62% | 6.17% | 0.46% | 29.77% | 25,905 |
| **Jun'26** | **63.62%** | **4.78%** | **0.36%** | **31.24%** | **43,413** |

### Key Trends

**🟢 Promoters — Stable & High**
- Holding steady at **63.62%** across the last four quarters — **no dilution**
- CEO Manish Grover increased his holdings +5.2% in Nov 2025

**🟡 FIIs — Peaked then trimmed**
- Rose from 0% (Mar'23) to a peak of **6.59%** (Sep'25)
- Trimmed to **4.78% (Jun'26)** — some profit-taking, but above the Mar'25 level

**🟢 Retail — Explosive base broadening**
- Shareholders exploded from **663 (Mar'23) to 43,413 (Jun'26)** — **65x increase in 3 years**
- Public holding grew to 31.24% — high retail participation adds volatility

---

## 7. Revenue Visibility & Growth Engines

| Metric | Value |
|--------|-------|
| **Operational Centres** | 119 (61 hospitals + 58 clinics/day-care) |
| **Operational Beds** | ~2,300 (+445 pipeline) |
| **Beds Added FY26** | 561 |
| **NABH-Accredited Centres** | 51 |
| **States Covered** | 23 |
| **SKUs (Products)** | 330+ |
| **Social Media Funnel** | 16M+ followers |
| **New Hospitals (Pipeline)** | Mathura 100-bed, Lucknow 160+ bed, Ahmedabad 150-bed, WB 60+ bed |

### Growth Levers
1. **Hospital expansion** — 561 beds added FY26 with ~445 more in pipeline; asset-light ₹3-4L/bed capex with <6-month payback claims
2. **Cross-sell flywheel** — hospitals generate patient base that buys 330+ SKU product portfolio (GM 86-91%)
3. **Health camps** — ~₹48-62L business per Meerut camp with ~30% IPD conversion
4. **International expansion** — UAE subsidiary + 51% UAE Ayurveda acquisition (Jan 2026); luxury wellness resort in Mandi, HP
5. **Digital** — Salesforce partnership, video OPD +65% YoY, 16M+ followers as cost-free customer funnel

---

## 8. Management Commentary

**CEO Manish Grover (Acharya Manish Ji)** leads the integrated Ayurveda healthcare push. Leadership extension approved Aug 2026 (5-year term).

### Key Management Messaging

> *"Integrated Ayurveda healthcare company"* —  hospital network + branded products + tech platform under one model.

| Theme | Commentary |
|-------|-----------|
| **Asset-light capex** | ₹3-4L/bed (vs ₹30-50L allopathy); break-even occupancy ~35%; <6-month payback on smaller hospitals |
| **Unit economics** | ~₹8,360/day/bed revenue potential |
| **Margin normalization** | Q1 FY27 OPM 41% vs 45% a year ago — "normalizing" off an elevated high base, not a structural decline |
| **Global ambition** | UAE subsidiary + 51% UAE acquisition (Jan 2026); luxury resort in Mandi, HP |
| **Customer acquisition** | 16M+ social followers + health camps replace doctor-referral dependence |

*Note: Full concall transcript not accessible; commentary compiled from news reports and investor communications.*

---

## 9. Technical Analysis (As of 13 Aug 2026)

**TradingView Summary:** **SELL** — Oscillators (Sell 1, Neutral 7, Buy 3) | MAs (Sell 13, Neutral 1, Buy 1)

> *Note vs 12 Aug: Oscillators have improved from Sell 2/Neutral 9/Buy 0 → Sell 1/Neutral 7/Buy 3. CCI, Momentum, and Williams %R have all flipped to Buy, and Hull MA(9) has turned Buy (the first MA to do so). Strong Sell has eased to Sell as oversold-reversal signals build.*

### Oscillators

| Indicator | Value | Signal |
|-----------|-------|--------|
| RSI (14) | 36.42 | Neutral |
| Stochastic %K (14,3,3) | 13.38 | Neutral |
| CCI (20) | -200.28 | **Buy** |
| ADX (14) | 14.84 | Neutral |
| Awesome Oscillator | -27.66 | Neutral |
| Momentum (10) | -47.65 | **Buy** |
| MACD Level (12,26) | -12.00 | **Sell** |
| Stoch RSI Fast (3,3,14,14) | 3.64 | Neutral |
| Williams %R (14) | -86.63 | **Buy** |
| Bull Bear Power | -81.94 | Neutral |
| Ultimate Oscillator (7,14,28) | 40.08 | Neutral |

### Moving Averages

| MA | Period | Value | Signal |
|----|--------|-------|--------|
| EMA | 10 | 551.08 | **Sell** |
| SMA | 10 | 563.44 | **Sell** |
| EMA | 20 | 561.91 | **Sell** |
| SMA | 20 | 564.23 | **Sell** |
| EMA | 30 | 568.92 | **Sell** |
| SMA | 30 | 568.30 | **Sell** |
| EMA | 50 | 581.81 | **Sell** |
| SMA | 50 | 578.74 | **Sell** |
| EMA | 100 | 606.09 | **Sell** |
| SMA | 100 | 615.11 | **Sell** |
| EMA | 200 | 616.23 | **Sell** |
| SMA | 200 | 654.86 | **Sell** |
| Ichimoku Base | 9,26,52,26 | 558.67 | Neutral |
| VWMA | 20 | 557.61 | **Sell** |
| Hull MA | 9 | 510.12 | **Buy** |

### Pivot Levels (Classic)

| Level | Price |
|-------|-------|
| **R3** | ₹693.38 |
| **R2** | ₹635.38 |
| **R1** | ₹610.77 |
| **Pivot** | **₹577.38** |
| S1 | ₹552.77 |
| **S2** | **₹519.38** |
| **S3** | **₹461.38** |

### EMA Ladder

```
EMA(10): ₹551 — CMP (₹520) BELOW
EMA(20): ₹562 — Below, descending
EMA(30): ₹569 — Below
EMA(50): ₹582 — Below
EMA(100): ₹606 — Below
EMA(200): ₹616 — Below (death cross zone)
SMA(200): ₹655 — Well below long-term average
```

**Technical Verdict:**
- **Price ₹519.60 trades BELOW every major moving average** — still a fully bearish long-term alignment (13 of 15 MAs in Sell)
- **However, the first signs of a potential reversal are building**: Hull MA(9) has flipped **Buy** (₹510.12, below current price) — the first MA to do so
- **Oscillators are improving** — CCI, Momentum, and Williams %R all flipped to **Buy** today (from Neutral/Sell on 12 Aug)
- **RSI at 36.42** — approaching but not yet oversold; **Stoch RSI at 3.64** and **Williams %R at -86.63** are deeply oversold, often precursors to a bounce
- **MACD still Sell** at -12.00 — momentum has not yet confirmed a reversal
- **ADX at 14.8** — no strong trend conviction (below 20), consistent with a pullback within a larger range
- **Price sits exactly on Classic S2 support (₹519)**; a break below opens ₹461 (S3), a reclaim of ₹552 (S1) then ₹577 pivot would signal reversal
- **Confirmed strong delivery (avg 51.4%)** supports that any bounce at current levels is backed by genuine accumulation

---

## 10. NSE Delivery Data Analysis

**✅ Data Confirmed (13 Aug 2026)** — NSE bhavcopy delivery data successfully retrieved.

> *Correction note: An initial attempt on 12 Aug was blocked by an intermittent NSE Akamai bot-challenge (`_abck` cookie). This has since cleared — delivery data is fully accessible from the current environment. See the delivery trend below.*

### JSLL Delivery Trend (Last 11 Sessions)

| Date | Close | Volume | Del Qty | Del % |
|------|-------|--------|---------|-------|
| 12-Aug | ₹511.50 | 888,284 | 464,325 | **52.27%** 🟢 |
| 11-Aug | ₹539.20 | 1,151,819 | 650,088 | **56.44%** 🟢 |
| 07-Aug | ₹598.10 | 531,096 | 291,844 | **54.95%** 🟢 |
| 06-Aug | ₹604.25 | 960,929 | 460,061 | **47.88%** 🟢 |
| 05-Aug | ₹579.25 | 345,655 | 159,901 | **46.26%** 🟢 |
| 04-Aug | ₹574.20 | 285,505 | 150,311 | **52.65%** 🟢 |
| 31-Jul | ₹586.15 | 646,373 | 310,867 | **48.09%** 🟢 |
| 30-Jul | ₹567.00 | 217,059 | 110,469 | **50.89%** 🟢 |
| 29-Jul | ₹564.90 | 621,946 | 311,747 | **50.12%** 🟢 |
| 28-Jul | ₹564.45 | 581,139 | 301,315 | **51.85%** 🟢 |
| 24-Jul | ₹554.80 | 503,062 | 273,407 | **54.35%** 🟢 |

**Avg delivery % (11 sessions): 51.4%**

### Interpretation
- **Delivery % has been consistently above 46% for 11 straight sessions** — averaging **51.4%**. This is **strong, genuine accumulation** quality, NOT speculative intraday churn.
- Every single session clears the **>40% delivery threshold** the checklist demands — and the 11-Aug session (the -13% results-day drop) showed the **highest delivery at 56.44%** on the biggest volume (1.15M). This is significant: it means the post-results decline was **absorbed by genuine strong-hand buying**, not panic churn.
- Cross-referencing with price action: the stock is grinding down from ₹604 → ₹511 on consistently high delivery. This pattern is consistent with **institutional/long-term accumulation during a price pullback** rather than distribution — the tell-tale distribution signature (low delivery on high volume) is absent.
- **Syrma cross-check applied:** a results-day volume spike on low ~15% delivery would be a churn/red-flag. Here 11-Aug delivered **56.44% on 2.2x volume** — the opposite, a healthy accumulation signal.

**What this means for the assessment:**
- ✅ The sustained >50% delivery **removes the accumulation-vs-churn uncertainty** flagged in the original note.
- ✅ Delivery quality **supports (not conflicts with) the fundamental accumulation thesis** — FII trim notwithstanding, the daily tape shows strong hands taking delivery.
- ⚠️ It does **not**, however, override the broken technicals (below all MAs). High delivery on a falling knife can precede a base, but the checklist still requires a price trigger before entry.

---

## 11. Bulk/Block Deals & Institutional Activity

**No bulk or block deals reported for Jeena Sikho in calendar 2026** in the news sources reviewed.

**What this means:** The FII position (peaked at 6.59% Sep'25, trimmed to 4.78% Jun'26) has changed through **gradual market purchases**, not visible block transactions. The stock's sharp moves (54% rally in 3 sessions after the Choice BUY, 13% crash post-Q1, -20% on 1 Jun) are mostly **retail-driven**, consistent with the BSE "B" group status.

> **✅ Delivery cross-check (13 Aug):** The 13% post-Q1 crash (10-11 Aug) delivered **56.44% on 2.2x volume** — this tempers the "retail churn" interpretation. The decline was absorbed by genuine strong-hand buying, suggesting the pullback is being **accumulated** rather than distributed. FII trimming is being absorbed by other strong hands and retail delivery-taking.

**SAST Disclosure:** No fund crossed the 5%/10% threshold disclosure was flagged in the news research for 2026.

---

## 12. Forward PE & Valuation

### EPS History

| Year | EPS (₹) | Growth |
|------|---------|-------|
| FY22 | 1.24 | — |
| FY23 | 2.71 | +119% |
| FY24 | 5.57 | +105% |
| FY25 | 7.30 | +31% |
| FY26 | **17.87** | **+145%** |
| TTM | 19.03 | — |

### Valuation at CMP (₹519.60)

| Metric | Value |
|--------|-------|
| **Trailing P/E (FY26)** | ~29x |
| **Industry P/E** | 28.3x |
| **PEG Ratio (3Y Profit CAGR)** | 0.31 |
| **Price/Book** | ~13.8x (₹519.60 / ₹37.6) |
| **Earnings Yield** | 4.93% |

### Analyst Consensus & Scenarios

**Choice Institutional Equities — BUY, Target ₹1,000 (reiterated 10 Aug 2026)**
- Expects **Revenue/EBITDA/PAT CAGR of 33.6% / 34.9% / 39.4% (FY26–FY29E)**
- Implied **~28x FY28E EPS**, PEG 0.8
- Prior targets: ₹900 (Oct 2025) → ₹1,000 — implies ~92% upside from ₹519

**Markets Mojo — SELL (8 Aug 2026)**
- Flags **P/B 16.1x "very expensive"**
- Bearish technicals: 3-mo -19%, 6-mo -16%, YTD -12%

### Scenario Analysis

| Scenario | Assumption | FY27E PAT | FY27E EPS | Forward P/E |
|----------|-----------|-----------|-----------|-------------|
| Conservative | 25% PAT growth | ₹278 Cr | ₹22.2 | **23x** |
| Moderate | 35% PAT growth (Choice avg) | ₹300 Cr | ₹24.0 | **22x** |
| Choice Broker | 39.4% PAT CAGR (FY29 basis) | ~₹310 Cr | ~₹24.8 | **21x** |

### Key Valuation Observations
1. **Trailing P/E ~29x looks reasonable** for a company with 85% 3Y profit CAGR and 70%+ ROCE — this is NOT an expensive valuation on a P/E basis
2. **The valuation concern is Price/Book (~14x)** — Screener flags this as a CON (13.9x). With ROE of 60%, a high P/B is defensible (P/B justified by high returns), but leaves no margin for ROE regression
3. **Forward P/E ~21-23x** at Choice's growth estimates — meaningfully cheaper than the trailing multiple if growth holds
4. **PEG 0.31** (Screener, on 3Y profit CAGR) suggests strong value relative to growth — but base effects inflate this (FY23-25 earnings grew from a low base)
5. **Risk symmetry:** If margins keep "normalizing" (from 44% OPM) and growth decelerates, the P/B expansion unwinds fast. If Choice's 33-39% CAGR materializes, the stock is undervalued.

---

## 13. Key Risks

| Risk | Severity | Detail |
|------|----------|--------|
| **Price/Book ~14x** | 🔴 HIGH | At 60% ROE the premium is defensible, but any ROE regression triggers sharp P/B de-rating. Screener flags 13.9x as a CON. |
| **Margin Normalization** | 🔴 HIGH | OPM fell from 45% (Q1FY26) to 41% (Q1FY27); Q1 profit quality: EBITDA margin -415bps, Finance costs +109%, Depreciation +59%. |
| **Profit Quality (Other Income)** | 🟡 MEDIUM | Other income surged **+1,212% to ₹14.02 Cr** in Q1 FY27 (from ₹1.07 Cr) — inflates reported PAT quality. EBIT growth only +11% vs PAT +28%. |
| **Extreme Volatility** | 🟡 MEDIUM | 54% rally in 3 sessions, -13% on results-day (10 Aug), -20% on 1 Jun. Retail-driven BSE "B" group small-cap. |
| **Low Institutional Cushion** | 🟡 MEDIUM | FIIs only 4.78%, DIIs 0.36%. FIIs trimmed from 6.59% peak. Mostly retail (31.24% public). |
| **Borrowing Step-Up** | 🟡 MEDIUM | Borrowings jumped ₹11 Cr → ₹127 Cr (Mar'26) to fund expansion — leverage rising from a low base. |
| **Business Model / Regulatory** | 🟡 MEDIUM | Operates in a direct-selling-adjacent consumer funnel. No regulatory red flags surfaced in 2026, but the model invites scrutiny. |
| **Unverified Catalysts** | 🟡 MEDIUM | Claims around a "Woveal/USPTO patent lawsuit against Estée Lauder" and "Glenmark-family ownership" could NOT be verified in any source — treat as unfounded. |
| **Competition** | 🟢 LOW | Dominates a thin peer set (Kaya, Lloyds Luxuries are loss-making). Expanding into Dabur/Patanjali's Ayurveda-product territory. |

---

## 14. Screener.in Pros & Cons

### Pros
- ✅ Company is expected to give good quarter
- ✅ Company has delivered good profit growth of **84.5% CAGR over last 5 years**
- ✅ Company has a good ROE track record: **3-Year ROE 49.6%**
- ✅ Healthy dividend payout of **19.1%**
- ✅ Debtor days improved from 51.4 to **31.8 days**

### Cons
- ❌ Stock is trading at **13.9 times its book value**

---

## 15. Bull vs Bear Case

### 🟢 Bull Case

| Argument | Evidence |
|----------|----------|
| **Explosive, debt-quality growth** | FY26: Revenue +71%, PAT +144%; 5-Yr profit CAGR 85%, 3-Yr 88%, TTM 103% |
| **Remarkable profitability** | OPM 44%, ROCE 70.7%, ROE 60%, CFO/OP 96%, FCF +₹231 Cr |
| **Asset-light hospital economics** | ₹3-4L/bed capex, <6-month payback, 35% break-even occupancy — highly scalable network model |
| **Cross-sell flywheel** | Hospitals feed a 330+ SKU product line (GM 86-91%) — 53% of revenue now products |
| **Undervalued on P/E** | Trailing ~29x, forward ~21-23x, PEG 0.31 — cheap for 85% profit CAGR |
| **Broker conviction** | Choice Institutional Equities: BUY, target ₹1,000 (~92% upside), 33-39% CAGR estimates |
| **Stable promoters** | 63.62% held steady across 4 quarters; CEO added +5.2% Nov'25 |
| **Growth runway** | 445 more beds in pipeline, UAE expansion, 51% UAE acquisition, luxury wellness resort |
| **Customer funnel moat** | 16M+ social followers = cost-free acquisition vs doctor-referral-dependent competitors |

### 🔴 Bear Case

| Argument | Evidence |
|----------|----------|
| **Margin normalization underway** | Q1 OPM 41% vs 45% a year ago; Finance costs +109%, Depreciation +59% eating into operating leverage |
| **Profit quality weak spot** | Other income +1,212% to ₹14.02 Cr; EBIT only +11% vs PAT +28% — PAT is flattered |
| **P/B ~14x, very expensive** | Screener CON; Markets Mojo "SELL" citing P/B 16.1x and bearish momentum |
| **Extreme volatility** | -13% post-Q1 (despite beat), -20% on 1 Jun, 54% in 3 sessions — no institutional cushion |
| **FIIs trimming** | FIIs fell from 6.59% (Sep'25) to 4.78% (Jun'26); retail 31.24% dominates float |
| **Technical breakdown** | Price below ALL 15 MAs; TradingView Strong Sell (Sell 16/Neutral 10/Buy 0); RSI 35, momentum negative |
| **Leverage step-up** | Borrowings ₹11 Cr → ₹127 Cr in one year to fund capex |
| **Unverified catalysts** | "Estée Lauder USPTO lawsuit" and "Glenmark-family ownership" claims not corroborated by any source |

---

## 16. 25-Point Swing Trading Checklist Assessment

| # | Checklist Item | Criterion | Evidence | Verdict |
|---|---------------|-----------|----------|---------|
| 1 | **Price Position** | Within 25% of 52W high or at ATH | 52W High ₹850, CMP ₹519.60. Distance: **39% below high** ❌ | ❌ **FAIL** |
| 2 | **Trend** | Clear uptrend, HH/HL visible | Price below ALL 15 MAs. Downtrend from ₹850. No HH/HL. | ❌ **FAIL** |
| 3 | **Volume Characteristics** | HVQ/HVY/HVE during breakouts | -13% on results day (11-Aug) delivered **56.44% on 2.2x volume** — healthy accumulation, not churn. But no breakout yet | ⚠️ CAUTION |
| 4 | **Clean Price Action** | Smooth/orderly candles | -20% (1 Jun), -13% (10 Aug), 54% in 3 sessions. Erratic | ❌ **FAIL** |
| 5 | **EMA Alignment** | 9>20>50>200, all up, price above | Price ₹520 below EMA10 ₹551, EMA20 ₹562, EMA50 ₹582, EMA200 ₹616. Inverted | ❌ **FAIL** |
| 6 | **Chart Pattern & Base** | Cup & Handle / Flat Base / etc. | Descending channel; sitting on S2 ₹519 support. No clear base | ⚠️ CAUTION |
| 7 | **Base Quality** | Well-formed, tightening action | Price testing support amid falling MAs; expansion unwinding | ⚠️ CAUTION |
| 8 | **ADR** | Suitable for trading style | ~4-5% daily range — wide stops needed | ⚠️ CAUTION |
| 9 | **Primary Uptrend** | Broader market supports longs | Stock in primary downtrend despite market breadth | ❌ **FAIL** |
| 10 | **Follow One Model** | Predefined strategy discipline | Aligns with swing/trading model | ✅ PASS |
| 11 | **Sector Strength** | Leading sector | Wellness/Ayurveda secular growth theme; only strong peer in thin set | ✅ PASS |
| 12 | **Tailwind** | Industry/macro tailwinds | Ayurveda healthcare demand, preventive-care boom, wellness resort/UAE expansion | ✅ PASS |
| 13 | **IPO Consideration** | IPO vs established | SME IPO 2022 → main board. Post-split/migration pricing discovery ongoing | ✅ PASS |
| 14 | **Price Action Strength** | Relative strength vs peers | Underperforming; down ~39% from high vs thin loss-making peer set | ❌ **FAIL** |
| 15 | **Sector & Govt Boost** | Policy support, reforms | Ayurveda/AYUSH govt push, wellness economy growth | ⚠️ CAUTION |
| 16 | **Fundamental Quality** | Healthy BS, improving business | ROCE 71%, ROE 60%, CFO/OP 96%, FCF +₹231 Cr. Exceptional — but P/B ~14x | ✅ PASS |
| 17 | **Quarterly Earnings Growth** | 30-50% growth | Q1 FY27: Rev +29%, PAT +28%. Solid if not stellar | ✅ PASS |
| 18 | **Delivery Percentage** | Genuine buying vs churn | **Confirmed strong — avg 51.4% over 11 sessions (range 46-56%), every day >40%.** Results-day (11-Aug) delivered 56.44%. Genuine accumulation, not churn | ✅ **PASS** |
| 19 | **News & Institutional Activity** | Positive news, MF/FII activity | Choice BUY ₹1,000, but FIIs trimming from peak (6.59→4.78%); Q4 one-offs | ⚠️ CAUTION |
| 20 | **Risk Management** | Entry, SL, target defined | Can set SL below ₹492 (52W low); but buying into a falling knife | ⚠️ CAUTION |
| 21 | **Market Environment** | Overall market supports | mixed | ⚠️ CAUTION |
| 22 | **Liquidity** | Sufficient volume | Retail-heavy but adequate liquidity | ✅ PASS |
| 23 | **Relative Strength** | Outperforming benchmark | Underperforming; below all MAs, negative momentum | ❌ **FAIL** |
| 24 | **Breakout Confirmation** | Decisive breakout with volume | No — price in confirmed downtrend, no breakout | ❌ **FAIL** |
| 25 | **Trading Psychology** | Avoid FOMO, follow rules | No entry signal; discipline dictates wait | ✅ PASS |

**Total Score: 11 / 25 — ❌ WEAK (Pass)**

| Score Range | Verdict |
|-------------|---------|
| 22-25 | ✅ Strong — consider entry |
| 17-21 | ⚠️ Moderate — needs catalyst |
| **< 17** | **❌ Weak — pass** |

### Key Weaknesses (Items to Watch for Improvement)
1. **🔴 Items 1, 2, 4, 5, 9, 14, 23, 24 — all price/trend-related FAILs.** The stock is in a genuine technical downtrend (below all MAs, negative momentum). No swing entry until the chart confirms a reversal.
2. **🟢 Delivery quality is genuinely strong** (Item 18 PASS — avg 51.4%), but does NOT offset the price/trend failures. Accumulation is present; the trigger is not.
3. **⚠️ Profit quality** — Q1 flattered by +1,212% other income; operating earnings grew slower than headline PAT.

### Trade Setup (If Considering Entry)
- **No entry now.** The 25-point score is a clear **11/25 — PASS**. Premature entry is against the checklist.
- **Entry trigger (wait for confirmation):** Reclaim of **₹552 (R1)** or preferably **₹577 pivot** on volume — delivery already clears >40%, so the missing catalyst is a price reclaim.
- **Alternative accumulation:** Strong-close near **₹461 (S3)** would offer a high-R:R long; delivery confirmation already present (avg 51%).
- **Note:** The delivery requirement (>40%) is **already satisfied** — the 25-point flow now hinges purely on a price/reversal trigger, not on delivery confirmation.
- **Stop Loss (if trading the bounce):** below ₹492 (52W low)
- **Target 1:** ₹552 (R1) → **Target 2:** ₹577 (pivot) → **Target 3:** ₹610 (R2 on a full reversal)

### Verdict Recommendation
**Do not initiate a swing position at ₹519.60.** This is a fundamentally excellent company (ROCE 71%, ROE 60%, strong FCF, cheap on P/E) trapped in a technical downtrend and rich on P/B — but with **confirmed strong delivery (avg 51.4%)** indicating genuine accumulation during the pullback. The checklist is unambiguous (11/25). **Set alerts for:**
1. ₹552/₹577 reclaim on volume → swing entry (delivery already confirmed >40%)
2. ₹461-492 accumulation zone → high-R:R long
3. Q2 FY27 results (expected Oct 2026) as margin-normalization catalyst

---

## 17. Final Verdict

### **CAUTION — High-Growth Integrated Ayurveda Leader, but Technically Broken & Rich on P/B**

Jeena Sikho is an **exceptionally high-quality, fast-growing Ayurveda healthcare business** — FY26 revenue +71%, PAT +144%, 70.7% ROCE, 60% ROE, positive FCF, and a stable promoter base. The **fundamental story is genuinely strong** and, on a P/E basis (trailing ~29x, forward ~21-23x), the stock is **not expensive** relative to its growth.

**However, three issues prevent a "buy" at ₹519.60:**

1. **📉 Technically Broken** — The price trades **below every major moving average** (TradingView: Sell, 13 of 15 MAs in Sell). RSI at 36 with room to fall. The stock has been in a sustained downtrend from its ₹850 high (down ~39%) and is sitting right on the S2 support at ₹519. There is no confirmed technical buy signal yet, though Hull MA(9) and three oscillators have just flipped Buy — early base-building signs.
2. **💹 Rich on Price/Book** — At ~14x book (Screener's sole CON), the market pays a massive premium based on today's exceptional 60% ROE. If margins keep "normalizing" (OPM already down from 45% to 41%) and ROE regresses toward the ~50% 3-yr average, the P/B premium unwinds sharply. Markets Mojo's SELL is anchored on exactly this.
3. **🎰 Profit Quality & Volatility** — Q1 profit was flattered by a **+1,212% surge in other income** (EBIT only grew +11% vs PAT +28%). This is a retail-driven small-cap (BSE "B" group) with -13%/-20% single-day crashes, and FIIs have been trimming, not adding.

> **✅ Delivery Update (13 Aug):** Earlier inconclusive delivery data has been **resolved** — NSE bhavcopy confirms delivery **averaging 51.4% over the last 11 sessions (range 46-56%)**, including 56.44% on the results-day volume spike. This is **genuine accumulation**, not speculative churn. The accumulation-vs-churn risk is now LOW, but the core technical/valuation concerns remain.

### What Would Change This View
- **Momentum reversal on the charts** — a decisive reclaim of the ₹552 R1 / ₹577 pivot on strong volume. Delivery already confirms >40%.
- **Profit quality recovery** — one quarter where operating earnings (ex-other income) grow in line with PAT, and OPM stabilizes above 42%
- **Institutional accumulation** — FII/DII holding meaningfully rising after the trim
- **Entry on support** — a clean dip to the ₹461 (S3) region would offer a better risk/reward for long-term accumulation

### Suitable Investor Profile

| Profile | Suitability |
|---------|-------------|
| Long-term (5+ year) investor | 🟡 **Wait for price stabilisation** near ₹461-492 support or a confirmed reversal; fundamentals excellent |
| Swing trader (1-6 months) | 🔴 **Avoid until MAs turn** — Strong Sell, no trend, buying the knife at S2 |
| Momentum trader | 🔴 **Avoid** — negative MACD & Momentum, below all MAs |
| Value investor | 🟡 **Mixed** — cheap on P/E (29x) but very expensive on P/B (~14x); wait for delivery confirmation |

> **Disclaimer:** For informational purposes only. Not investment advice. Data sourced from Screener.in standalone view (logged-in, 27 metrics), TradingView NSE (real-time), NSE bhavcopy (delivery data confirmed, avg 51.4%), and news research. The author may hold positions in securities discussed. Independent due diligence recommended before any investment decision.

---

*Generated by PulkitAIAssistant using DeepSeek Chat model*